Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; 18 of the 57 sources its claims cite were checked for support.

Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial

Open access

Published version of a preprint

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are widely used for treating neuropsychiatric disorders. However, the exact mechanism of action and why effects can take several weeks to manifest is not clear. The hypothesis of neuroplasticity is supported by preclinical studies, but the evidence in humans is limited. Here, we investigate the effects of the SSRI escitalopram on presynaptic density as a proxy for synaptic plasticity. In a double-blind placebo-controlled study (NCT04239339), 32 healthy participants with no history of psychiatric or cognitive disorders were randomized to receive daily oral dosing of either 20 mg escitalopram ( n = 17) or a placebo ( n = 15). After an intervention period of 3–5 weeks, participants underwent a [ 11 C]UCB-J PET scan (29 with full arterial input function) to quantify synaptic vesicle glycoprotein 2A (SV2A) density in the hippocampus and the neocortex. Whereas we find no statistically significant group difference in SV2A binding after an average of 29 (range: 24–38) days of intervention, our secondary analyses show a time-dependent effect of escitalopram on cerebral SV2A binding with positive associations between [ 11 C]UCB-J binding and duration of escitalopram intervention. Our findings suggest that brain synaptic plasticity evolves over 3–5 weeks in healthy humans following daily intake of escitalopram. This is the first in vivo evidence to support the hypothesis of neuroplasticity as a mechanism of action for SSRIs in humans and it offers a plausible biological explanation for the delayed treatment response commonly observed in patients treated with SSRIs. While replication is warranted, these results have important implications for the design of future clinical studies investigating the neurobiological effects of SSRIs.

Overview

CoChat Summary

TL;DR

In a double-blind placebo-controlled trial in 32 healthy adults, 3–5 weeks of escitalopram did not significantly change [11C]UCB-J PET SV2A binding in the hippocampus or neocortex versus placebo. Secondary analyses found a time-dependent positive association between escitalopram intervention duration and neocortical SV2A binding, suggesting delayed synaptic plasticity.

Key findings

  • Primary group comparison showed no statistically significant difference after an average of 29 days: hippocampus VT was 15.1 (2.2) vs. 14.3 (1.9) mL/cm3 for escitalopram vs. placebo (Cohen’s d = 0.43, 95% CI [−0.36, 1.20], p = 0.26); neocortex VT was 18.3 (2.5) vs. 17.6 (2.0) mL/cm3 (d = 0.31, 95% CI [−0.47, 1.08], p = 0.41).
  • Secondary duration analysis found a positive time-dependent effect in the escitalopram group: neocortex +0.41 mL/cm3 per day (rρ = 0.46, p = 0.016) vs. −0.12 mL/cm3 per day for placebo (rρ = −0.18, p = 0.38); hippocampus +0.25 mL/cm3 per day (rρ = 0.31, p = 0.11) vs. −0.14 mL/cm3 per day for placebo (rρ = −0.22, p = 0.26). With age, sex, and IQ covariates, effects were neocortex +0.47 mL/cm3 per day (rρ = 0.58, p = 0.003) and hippocampus +0.30 mL/cm3 per day (rρ = 0.40, p = 0.048).
  • No association was found between s-escitalopram concentration and [11C]UCB-J VT: neocortex +0.81 mL/cm3 per log[ng/L] (rρ = 0.18, p = 0.48); hippocampus +0.39 mL/cm3 per log[ng/L] (rρ = 0.10, p = 0.70).
  • Exploratory analyses found no significant escitalopram effects on hippocampus volume or cortical thickness.

Methods

  • Double-blind, semi-randomized, placebo-controlled study in 32 healthy participants with no history of psychiatric or cognitive disorders; randomized to 20 mg escitalopram daily (n = 17) or placebo (n = 15), with a 3–5 week intervention and PET after an average of 29 days (range 24–38); 29 participants had a full arterial input function.
  • [11C]UCB-J PET quantified SV2A binding using the one-tissue compartment model total volume of distribution (VT) in hippocampus and neocortex as primary outcome; SRTM2 BPND was a complementary analysis.
  • Group comparisons used Welch two-sample t-tests and general linear models with age, sex, and IQ covariates; secondary analyses used linear regressions with group-by-intervention-duration interaction terms and Bonferroni-Holm correction.

Limitations

  • Stated: no baseline [11C]UCB-J PET scans were included, so the study assumes no pre-intervention group differences in cerebral SV2A binding.
  • Stated: the sample size was targeted to detect larger effect sizes, limiting detection of subtler differences and subgroup differences; replication is warranted, ideally with a longer intervention range and more subjects.
  • Stated: SV2A is a proxy for presynaptic density, and changes could reflect number of vesicles per synapse or differential effects on excitatory and inhibitory synapses; the white matter reference region contains some SV2A and may overestimate the non-displaceable compartment.
  • Evident from the text: the primary VT analysis included only 12 placebo participants with full arterial input function, reducing power, and the duration effect comes from a within-group secondary analysis over a relatively narrow 24–38 day range, so causality cannot be established from that association alone.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41380-023-02285-8

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Effects of escitalopram on SV2A density. Comparison of [11C]UCB-J binding in healthy individuals following 3-5 weeks of intervention with escitalopram (n = 17) or placebo (n = 12). [11C]UCB-J total volume of distribution (VT) quantified using the 1TCM (n = 29).
Fig. 1 Effects of escitalopram on SV2A density. Comparison of [11C]UCB-J binding in healthy individuals following 3-5 weeks of intervention with escitalopram (n = 17) or placebo (n = 12). [11C]UCB-J total volume of distribution (VT) quantified using the 1TCM (n = 29).CC BY · PubMed Central
Fig. 2 Time-dependent effects of escitalopram on SV2A density. Relationship between [11C]UCB-J binding (VT) and the duration of the intervention for the placebo group (n = 12) and the escitalopram group (n = 17) in the neocortex (A) and the hippocampus (B). The shaded grey area represents the 95% CI.
Fig. 2 Time-dependent effects of escitalopram on SV2A density. Relationship between [11C]UCB-J binding (VT) and the duration of the intervention for the placebo group (n = 12) and the escitalopram group (n = 17) in the neocortex (A) and the hippocampus (B). The shaded grey area represents the 95% CI.CC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 2 Not valid · 23 Not checked · 52 Own results and interpretations

28 more claims

Create a free account to see all 85 claims and to verify the 39 references still open.

See all claims — free account
  • Probably not a substantial claim. 28
  • It may state two separate claims as one. 33

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 62 references

Research works printed but not linked: 2

  1. Reynolds CR, Kamphaus RW. Introduction to the Reynolds Intellectual Assessment Scales and the Reynolds Intellectual Screening Test. Contemporary intellectual assessment: theories, tests, and issues., New York, NY, US: The Guilford Press; 2005. p. 461–83.
  2. Lipsitz SR, Leong T, Ibrahim J, Lipshultz S. A partial correlation coefficient and coefficient of determination for multivariate normal repeated measures data. J R Stat Soc: Ser D (Stat). 2001;50:87–95.

Cited by

See all 53

Metadata

Authors
Johansen, A., Armand, S., Plavén-Sigray, P., Nasser, A., Ozenne, B., Petersen, I. N., Keller, S. H., Madsen, J., Beliveau, V., Møller, K., Vassilieva, A., Langley, C., Svarer, C., Stenbæk, D. S., Sahakian, B. J., & Knudsen, G. M.
Affiliations
  • University of Copenhagen (DK)
  • Rigshospitalet (DK)
  • Copenhagen University Hospital (DK)
  • Innsbruck Medical University (AT)
  • University of Cambridge (GB)
Corresponding author
Knudsen, Gitte M.
Venue
Molecular Psychiatry
Published
2023-10
Volume
28
Issue
10
Pages
4272-4279
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W4387451491
Cited by
53
References
62
Citations by year
2026: 12 · 2025: 21 · 2024: 20
FWCI
8.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (acceptedVersion, other-oa)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
Funders
  • Lundbeckfonden (R281-2018-131)
  • Det Frie Forskningsråd (8020-00414B)
  • Rigshospitalet (R216-A9684)
  • Vetenskapsrådet (2021-00462)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
escitalopram, selective serotonin reuptake inhibitors, synaptic plasticity, presynaptic density, SV2A, hippocampus, neocortex, neuroplasticity, mechanism of action, delayed treatment response, healthy volunteers
MeSH terms
Escitalopram, Brain, Humans, Synapses, Citalopram, Selective Serotonin Reuptake Inhibitors, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial. https://app.cochat.ai/papers/10.1038/s41380-023-02285-8
The paper
Johansen, A., Armand, S., Plavén-Sigray, P., Nasser, A., Ozenne, B., Petersen, I. N., Keller, S. H., Madsen, J., Beliveau, V., Møller, K., Vassilieva, A., Langley, C., Svarer, C., Stenbæk, D. S., Sahakian, B. J., & Knudsen, G. M. (2023). Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial. Molecular Psychiatry. https://doi.org/10.1038/s41380-023-02285-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.